Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Details

Connection

Jennifer Taylor-Cousar to Humans

This is a "connection" page, showing publications Jennifer Taylor-Cousar has written about Humans.

 
Connection Strength
  
 
 
1.242
  
  1. Jain R, Peng G, Lee M, Keller A, Cosmich S, Reddy S, West NE, Kazmerski TM, Goralski JL, Flume PA, Roe AH, Hadjiliadis D, Uluer A, Mody S, Ladores S, Taylor-Cousar JL. Impact of Cystic Fibrosis Transmembrane Conductance Regulator Modulators on Maternal Outcomes During and After Pregnancy. Chest. 2025 Feb; 167(2):348-361.
    View in: PubMed
    Score: 0.024
  2. Taylor-Cousar JL, Sole A, Jain R. Pregnancy and fertility in people with cystic fibrosis following lung transplantation. Curr Opin Pulm Med. 2024 Nov 01; 30(6):652-659.
    View in: PubMed
    Score: 0.024
  3. Kazmerski TM, Stransky OM, Lee M, Prangley KA, Jain R, Georgiopoulos AM, Shaw DS, Taylor-Cousar J. Assessing the health impacts of parenthood on people with cystic fibrosis: the HOPeCF prospective cohort protocol. BMJ Open Respir Res. 2024 Aug 28; 11(1).
    View in: PubMed
    Score: 0.024
  4. Mall MA, Burgel PR, Castellani C, Davies JC, Salathe M, Taylor-Cousar JL. Cystic fibrosis. Nat Rev Dis Primers. 2024 Aug 08; 10(1):53.
    View in: PubMed
    Score: 0.024
  5. Taylor-Cousar JL, Janney R, Middleton PG, Jain R, Nightingale J, West NE, Shteinberg M, Velez D, Kazmerski TM. A provider survey assessing fetal impact of CFTR modulator use in males with CF during assisted and unassisted reproduction and partner pregnancy. J Cyst Fibros. 2024 May; 23(3):412-416.
    View in: PubMed
    Score: 0.023
  6. Beswick DM, Khatiwada A, Miller JE, Humphries SM, Wilson A, Vladar EK, Lynch DA, Taylor-Cousar JL. Impact of highly effective modulator therapy on chronic rhinosinusitis and health status: 2-year follow-up. J Cyst Fibros. 2024 Mar; 23(2):214-218.
    View in: PubMed
    Score: 0.022
  7. Taylor-Cousar JL, Boyd AC, Alton EWFW, Polineni D. Genetic therapies in cystic fibrosis. Curr Opin Pulm Med. 2023 11 01; 29(6):615-620.
    View in: PubMed
    Score: 0.022
  8. Taylor-Cousar JL, Robinson PD, Shteinberg M, Downey DG. CFTR modulator therapy: transforming the landscape of clinical care in cystic fibrosis. Lancet. 2023 09 30; 402(10408):1171-1184.
    View in: PubMed
    Score: 0.022
  9. Jain R, Kazmerski TM, Taylor-Cousar JL. The modern landscape of fertility, pregnancy, and parenthood in people with cystic fibrosis. Curr Opin Pulm Med. 2023 11 01; 29(6):595-602.
    View in: PubMed
    Score: 0.022
  10. Taylor-Cousar JL, Shteinberg M, Cohen-Cymberknoh M, Jain R. The Impact of Highly Effective Cystic Fibrosis Transmembrane Conductance Regulator Modulators on the Health of Female Subjects With Cystic Fibrosis. Clin Ther. 2023 03; 45(3):278-289.
    View in: PubMed
    Score: 0.021
  11. Britto CJ, Taylor-Cousar JL. Cystic Fibrosis in the Era of Highly Effective CFTR Modulators. Clin Chest Med. 2022 12; 43(4):xiii-xvi.
    View in: PubMed
    Score: 0.021
  12. McGarry ME, McColley SA, Taylor-Cousar J. In response to "who are the 10%? - Non eligibility of cystic fibrosis (CF) patients for highly effective modulator therapies". Respir Med. 2022 10; 202:106953.
    View in: PubMed
    Score: 0.021
  13. Jia S, Taylor-Cousar JL. Cystic Fibrosis Modulator Therapies. Annu Rev Med. 2023 01 27; 74:413-426.
    View in: PubMed
    Score: 0.021
  14. Jain R, Magaret A, Vu PT, VanDalfsen JM, Keller A, Wilson A, Putman MS, Mayer-Hamblett N, Esther CR, Taylor-Cousar JL. Prospectively evaluating maternal and fetal outcomes in the era of CFTR modulators: the MAYFLOWERS observational clinical trial study design. BMJ Open Respir Res. 2022 06; 9(1).
    View in: PubMed
    Score: 0.020
  15. Beswick DM, Humphries SM, Miller JE, Balkissoon CD, Khatiwada A, Vladar EK, Ramakrishnan VR, Lynch DA, Taylor-Cousar JL. Objective and patient-based measures of chronic rhinosinusitis in people with cystic fibrosis treated with highly effective modulator therapy. Int Forum Allergy Rhinol. 2022 11; 12(11):1435-1438.
    View in: PubMed
    Score: 0.020
  16. Kramer-Golinkoff E, Camacho A, Kramer L, Taylor-Cousar JL. A survey: Understanding the health and perspectives of people with CF not benefiting from CFTR modulators. Pediatr Pulmonol. 2022 05; 57(5):1253-1261.
    View in: PubMed
    Score: 0.020
  17. Kazmerski TM, Jain R, Lee M, Taylor-Cousar JL. Parenthood impacts short-term health outcomes in people with cystic fibrosis. J Cyst Fibros. 2022 07; 21(4):662-668.
    View in: PubMed
    Score: 0.020
  18. Beswick DM, Humphries SM, Balkissoon CD, Strand M, E Miller J, Khatiwada A, Vladar EK, Lynch DA, Taylor-Cousar JL. Olfactory dysfunction in people with cystic fibrosis with at least one copy of F508del. Int Forum Allergy Rhinol. 2022 07; 12(7):963-966.
    View in: PubMed
    Score: 0.020
  19. Beswick DM, Humphries SM, Balkissoon CD, Strand M, Vladar EK, Lynch DA, Taylor-Cousar JL. Impact of Cystic Fibrosis Transmembrane Conductance Regulator Therapy on Chronic Rhinosinusitis and Health Status: Deep Learning CT Analysis and Patient-reported Outcomes. Ann Am Thorac Soc. 2022 01; 19(1):12-19.
    View in: PubMed
    Score: 0.020
  20. Sriningsih AP, Lung NP, Sulistyo F, Aronson SA, Aronson RK, Taylor-Cousar JL. EVALUATING THE EFFICACY OF HUMAN BRONCHIECTASISBASED ANTIBIOTIC THERAPY IN THE TREATMENT OF ORANGUTAN RESPIRATORY DISEASE SYNDROME. J Zoo Wildl Med. 2021 Dec; 52(4):1205-1216.
    View in: PubMed
    Score: 0.020
  21. Barry PJ, Taylor-Cousar JL. Triple combination cystic fibrosis transmembrane conductance regulator modulator therapy in the real world - opportunities and challenges. Curr Opin Pulm Med. 2021 11 01; 27(6):554-566.
    View in: PubMed
    Score: 0.020
  22. Beswick DM, Humphries SM, Balkissoon CD, Strand M, Vladar EK, Ramakrishnan VR, Taylor-Cousar JL. Olfactory dysfunction in cystic fibrosis: Impact of CFTR modulator therapy. J Cyst Fibros. 2022 03; 21(2):e141-e147.
    View in: PubMed
    Score: 0.019
  23. Jain R, Kazmerski TM, Aitken ML, West N, Wilson A, Bozkanat KM, Montemayor K, von Berg K, Sjoberg J, Poranski M, Taylor-Cousar JL. Challenges Faced by Women with Cystic Fibrosis. Clin Chest Med. 2021 09; 42(3):517-530.
    View in: PubMed
    Score: 0.019
  24. Jain R, Kazmerski TM, Zuckerwise LC, West NE, Montemayor K, Aitken ML, Cheng E, Roe AH, Wilson A, Mann C, Ladores S, Sjoberg J, Poranski M, Taylor-Cousar JL. Pregnancy in cystic fibrosis: Review of the literature and expert recommendations. J Cyst Fibros. 2022 05; 21(3):387-395.
    View in: PubMed
    Score: 0.019
  25. Kazmerski TM, West NE, Jain R, Uluer A, Georgiopoulos AM, Aitken ML, Taylor-Cousar JL. Family-building and parenting considerations for people with cystic fibrosis. Pediatr Pulmonol. 2022 02; 57 Suppl 1:S75-S88.
    View in: PubMed
    Score: 0.019
  26. Guimbellot JS, Taylor-Cousar JL. Combination CFTR modulator therapy in children and adults with cystic fibrosis. Lancet Respir Med. 2021 07; 9(7):677-679.
    View in: PubMed
    Score: 0.019
  27. Taylor-Cousar JL, Jain R. Maternal and fetal outcomes following elexacaftor-tezacaftor-ivacaftor use during pregnancy and lactation. J Cyst Fibros. 2021 05; 20(3):402-406.
    View in: PubMed
    Score: 0.019
  28. Middleton PG, Taylor-Cousar JL. Development of elexacaftor - tezacaftor - ivacaftor: Highly effective CFTR modulation for the majority of people with Cystic Fibrosis. Expert Rev Respir Med. 2021 06; 15(6):723-735.
    View in: PubMed
    Score: 0.019
  29. Ramos KJ, Pilewski JM, Taylor-Cousar JL. Challenges in the use of highly effective modulator treatment for cystic fibrosis. J Cyst Fibros. 2021 05; 20(3):381-387.
    View in: PubMed
    Score: 0.019
  30. Taylor-Cousar JL, Maier L, Downey GP, Wechsler ME. Restarting Respiratory Clinical Research in the Era of the Coronavirus Disease 2019 Pandemic. Chest. 2021 03; 159(3):1173-1181.
    View in: PubMed
    Score: 0.018
  31. Beswick DM, Humphries SM, Balkissoon CD, Vladar EK, Ramakrishnan VR, Lynch DA, Taylor-Cousar JL. Machine learning evaluates improvement in sinus computed tomography opacification with CFTR modulator therapy. Int Forum Allergy Rhinol. 2021 05; 11(5):953-954.
    View in: PubMed
    Score: 0.018
  32. Taylor-Cousar JL, Jain R, Kazmerski TM, Aitken ML, West NE, Wilson A, Middleton PG, Nash EF. Concerns regarding the safety of azithromycin in pregnancy - relevance for women with cystic fibrosis. J Cyst Fibros. 2021 05; 20(3):395-396.
    View in: PubMed
    Score: 0.018
  33. Shteinberg M, Taylor-Cousar JL. Impact of CFTR modulator use on outcomes in people with severe cystic fibrosis lung disease. Eur Respir Rev. 2020 Mar 31; 29(155).
    View in: PubMed
    Score: 0.017
  34. Nash EF, Middleton PG, Taylor-Cousar JL. Outcomes of pregnancy in women with cystic fibrosis (CF) taking CFTR modulators - an international survey. J Cyst Fibros. 2020 07; 19(4):521-526.
    View in: PubMed
    Score: 0.017
  35. Taylor-Cousar JL, Evans TA, Cutting GR, Sharma N. Potentially lethal cystic fibrosis gene variant in the orangutan. Am J Primatol. 2021 12; 83(12):e23097.
    View in: PubMed
    Score: 0.017
  36. Downey DG, Taylor-Cousar J. Letter to the editor: Challenges and opportunities in the development of future CFTR modulator options for people with CF. J Cyst Fibros. 2020 01; 19(1):e1-e2.
    View in: PubMed
    Score: 0.017
  37. Lommatzsch ST, Taylor-Cousar JL. The combination of tezacaftor and ivacaftor in the treatment of patients with cystic fibrosis: clinical evidence and future prospects in cystic fibrosis therapy. Ther Adv Respir Dis. 2019 Jan-Dec; 13:1753466619844424.
    View in: PubMed
    Score: 0.016
  38. Bratcher PE, Hunt KC, Pickard K, Taylor-Cousar JL. Positive clinical response to ivacaftor treatment in an individual with the CFTR genotype F508del/V456A. J Cyst Fibros. 2019 03; 18(2):e9-e10.
    View in: PubMed
    Score: 0.016
  39. Heltshe SL, Taylor-Cousar JL. Let's talk about sex: Behaviors, experience and health care utilization in young women with CF. J Cyst Fibros. 2018 01; 17(1):5-6.
    View in: PubMed
    Score: 0.015
  40. Taylor-Cousar JL, Jain M, Barto TL, Haddad T, Atkinson J, Tian S, Tang R, Marigowda G, Waltz D, Pilewski J. Lumacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease homozygous for F508del-CFTR. J Cyst Fibros. 2018 03; 17(2):228-235.
    View in: PubMed
    Score: 0.015
  41. Taylor-Cousar JL, Munck A, McKone EF, van der Ent CK, Moeller A, Simard C, Wang LT, Ingenito EP, McKee C, Lu Y, Lekstrom-Himes J, Elborn JS. Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del. N Engl J Med. 2017 11 23; 377(21):2013-2023.
    View in: PubMed
    Score: 0.015
  42. Donaldson SH, Solomon GM, Zeitlin PL, Flume PA, Casey A, McCoy K, Zemanick ET, Mandagere A, Troha JM, Shoemaker SA, Chmiel JF, Taylor-Cousar JL. Pharmacokinetics and safety of cavosonstat (N91115) in healthy and cystic fibrosis adults homozygous for F508DEL-CFTR. J Cyst Fibros. 2017 May; 16(3):371-379.
    View in: PubMed
    Score: 0.014
  43. Heltshe SL, Godfrey EM, Josephy T, Aitken ML, Taylor-Cousar JL. Pregnancy among cystic fibrosis women in the era of CFTR modulators. J Cyst Fibros. 2017 Nov; 16(6):687-694.
    View in: PubMed
    Score: 0.014
  44. Taylor-Cousar JL, Janssen JS, Wilson A, Clair CG, Pickard KM, Jones MC, Brayshaw SJ, Chacon CS, Barboa CM, Sontag MK, Accurso FJ, Nichols DP, Saavedra MT, Nick JA. Glucose >200?mg/dL during Continuous Glucose Monitoring Identifies Adult Patients at Risk for Development of Cystic Fibrosis Related Diabetes. J Diabetes Res. 2016; 2016:1527932.
    View in: PubMed
    Score: 0.014
  45. Kuk K, Taylor-Cousar JL. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects. Ther Adv Respir Dis. 2015 Dec; 9(6):313-26.
    View in: PubMed
    Score: 0.013
  46. Taylor-Cousar J, Niknian M, Gilmartin G, Pilewski JM. Effect of ivacaftor in patients with advanced cystic fibrosis and a G551D-CFTR mutation: Safety and efficacy in an expanded access program in the United States. J Cyst Fibros. 2016 Jan; 15(1):116-22.
    View in: PubMed
    Score: 0.012
  47. Taylor-Cousar JL, Wiley C, Felton LA, St Clair C, Jones M, Curran-Everett D, Poch K, Nichols DP, Solomon GM, Saavedra MT, Accurso FJ, Nick JA. Pharmacokinetics and tolerability of oral sildenafil in adults with cystic fibrosis lung disease. J Cyst Fibros. 2015 Mar; 14(2):228-36.
    View in: PubMed
    Score: 0.012
  48. Taylor-Cousar JL. Hypoventilation in cystic fibrosis. Semin Respir Crit Care Med. 2009 Jun; 30(3):293-302.
    View in: PubMed
    Score: 0.008
  49. Taylor-Cousar JL, Zariwala MA, Burch LH, Pace RG, Drumm ML, Calloway H, Fan H, Weston BW, Wright FA, Knowles MR. Histo-blood group gene polymorphisms as potential genetic modifiers of infection and cystic fibrosis lung disease severity. PLoS One. 2009; 4(1):e4270.
    View in: PubMed
    Score: 0.008
  50. Jathal I, Stransky OM, Wright CE, Prangley A, Tangpricha V, Jain R, Taylor-Cousar JL, Hughan KS, Ladores-Barrett S, West NE, Sawicki GS, Kazmerski TM. Fertility and family-building experiences and perspectives of males with cystic fibrosis. Reprod Biol Endocrinol. 2025 Jun 02; 23(1):85.
    View in: PubMed
    Score: 0.006
  51. Godfrey EM, Magaret A, Roe A, Taylor-Cousar JL, Walker P, Langfelder-Schwind E, Kazmerski TM, Jain R, Mody SK, Uluer A, West NE, Bray LA, Hsu C, Fiastro A, Stukovsky KDH, Hadjiliadis D, Solomon GM, Ladores-Barrett S. Contraceptive use and pregnancy in cystic fibrosis: Survey findings from 10 cystic fibrosis centers. J Cyst Fibros. 2025 May; 24(3):491-497.
    View in: PubMed
    Score: 0.006
  52. Zemanick ET, Ramsey B, Sands D, McKone EF, Fajac I, Taylor-Cousar JL, Mall MA, Konstan MW, Nair N, Zhu J, Arteaga-Solis E, Van Goor F, McGarry L, Prieto-Centurion V, Sosnay PR, Bozic C, Waltz D, Mayer-Hamblett N. Sweat chloride reflects CFTR function and correlates with clinical outcomes following CFTR modulator treatment. J Cyst Fibros. 2025 Mar; 24(2):246-254.
    View in: PubMed
    Score: 0.006
  53. Keating C, Yonker LM, Vermeulen F, Prais D, Linnemann RW, Trimble A, Kotsimbos T, Mermis J, Braun AT, O'Carroll M, Sutharsan S, Ramsey B, Mall MA, Taylor-Cousar JL, McKone EF, Tullis E, Floreth T, Michelson P, Sosnay PR, Nair N, Zahigian R, Martin H, Ahluwalia N, Lam A, Horsley A. Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials. Lancet Respir Med. 2025 Mar; 13(3):256-271.
    View in: PubMed
    Score: 0.006
  54. Hoppe JE, Kasi AS, Pittman JE, Jensen R, Thia LP, Robinson P, Tirakitsoontorn P, Ramsey B, Mall MA, Taylor-Cousar JL, McKone EF, Tullis E, Salinas DB, Zhu J, Chen YC, Rodriguez-Romero V, Sosnay PR, Davies G. Vanzacaftor-tezacaftor-deutivacaftor for children aged 6-11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial. Lancet Respir Med. 2025 Mar; 13(3):244-255.
    View in: PubMed
    Score: 0.006
  55. Lovinsky-Desir S, Riley IL, Bryant-Stephens T, De Keyser H, Forno E, Kozik AJ, Louisias M, Matsui EC, Sheares BJ, Thakur N, Apter AJ, Beck AF, Bentley-Edwards KL, Berkowitz C, Braxton C, Dean J, Jones CP, Koinis-Mitchell D, Okelo SO, Taylor-Cousar JL, Teach SJ, Wechsler ME, Gaffin JM, Federico MJ. Research Priorities in Pediatric Asthma Morbidity: Addressing the Impacts of Systemic Racism on Children with Asthma in the United States. An Official American Thoracic Society Workshop Report. Ann Am Thorac Soc. 2024 Oct; 21(10):1349-1364.
    View in: PubMed
    Score: 0.006
  56. Liu CM, Fischer JL, Alt JA, Bodner TE, Chowdhury NI, Getz AE, Hwang PH, Kimple AJ, Mace JC, Smith TL, Soler ZM, Goss CH, Taylor-Cousar JL, Saavedra MT, Beswick DM. Impact of sinus surgery in people with cystic fibrosis and chronic rhinosinusitis in the era of highly effective modulator therapy: Protocol for a prospective observational study. PLoS One. 2024; 19(9):e0310986.
    View in: PubMed
    Score: 0.006
  57. Costa E, Girotti S, Mathieu C, Castellani C, Ross JS, Taylor-Cousar JL, Leufkens HGM. Differential times of submission and approval of CFTR modulators for the treatment of Cystic Fibrosis in the United States and the European Union. J Cyst Fibros. 2025 Jan; 24(1):125-132.
    View in: PubMed
    Score: 0.006
  58. Han EJ, Liu CM, Fischer JL, Mace JC, Markarian K, Alt JA, Bodner TE, Chowdhury NI, Eshaghian PH, Gao YA, Getz AE, Hwang PH, Khanwalkar A, Kimple AJ, Lee JT, Li DA, Norris M, Nayak JV, Owens C, Patel ZM, Poch K, Schlosser RJ, Smith KA, Smith TL, Soler ZM, Suh JD, Turner GA, Wang MB, Taylor-Cousar JL, Saavedra MT, Beswick DM. Impact of sociodemographic status and sex on chronic rhinosinusitis and olfaction in people with cystic fibrosis. Int Forum Allergy Rhinol. 2024 Nov; 14(11):1700-1713.
    View in: PubMed
    Score: 0.006
  59. Gramegna A, Addy C, Allen L, Bakkeheim E, Brown C, Daniels T, Davies G, Davies JC, De Marie K, Downey D, Felton I, Hafkemeyer S, Hamouda S, Kendall V, Lindberg U, Macek M, Mayell S, Pearlsman O, Schechter MS, Salvatori L, Sands D, Schwarz C, Shteinberg M, Taylor J, Taylor-Cousar JL, Taylor-Robinson D, Watkins B, Verkleij M, Bevan A, Castellani C, Drevinek P, Gartner S, Lammertyn E, Landau EEC, Middleton PG, Plant BJ, Smyth AR, van Koningsbruggen-Rietschel S, Burgel PR, Southern KW. Standards for the care of people with cystic fibrosis (CF); Planning for a longer life. J Cyst Fibros. 2024 May; 23(3):375-387.
    View in: PubMed
    Score: 0.006
  60. Miller JE, Oh E, Khatiwada A, Humphries SM, Wilson A, Vladar EK, Lynch DA, Taylor-Cousar JL, Beswick DM. Two-Year Impact of Highly Effective Modulator Therapy on Olfactory Dysfunction. Laryngoscope. 2024 Jun; 134(6):2492-2494.
    View in: PubMed
    Score: 0.006
  61. Jia S, Wang Y, Ross MH, Zuckerman JB, Murray S, Han MK, Cahalan SE, Lenhan BE, Best RN, Taylor-Cousar JL, Simon RH, Fitzgerald LJ, Troost JP, Sood SL, Gifford AH. Association between CFTR modulators and changes in iron deficiency markers in cystic fibrosis. J Cyst Fibros. 2024 Sep; 23(5):878-884.
    View in: PubMed
    Score: 0.006
  62. Kazmerski TM, Moy C, Aliaj E, Hudson J, Wright B, Poranski M, Sjoberg J, Taylor-Cousar JL, Georgiopoulos AM, Ladores SL, Trimble A, Tangpricha V, Khan FN, Ramasamy R, Leitner DV, West NE, Santos RD, Stransky OM, Wilson A, Keller A, Jain R. Prioritizing sexual and reproductive health research and care for people with cystic fibrosis: A 2023 workshop report from the Cystic Fibrosis Foundation Sexual Health, Reproduction, and Gender (SHARING) Research Working Group. J Cyst Fibros. 2024 Jul; 23(4):639-646.
    View in: PubMed
    Score: 0.006
  63. Liu CM, Han EJ, Fischer JL, Mace JC, Mattos JL, Markarian K, Alt JA, Bodner TE, Chowdhury NI, Eshaghian PH, Getz AE, Hwang PH, Khanwalkar A, Kimple AJ, Lee JT, Li DA, Norris M, Nayak JV, Owens C, Patel ZM, Poch K, Schlosser RJ, Smith KA, Smith TL, Soler ZM, Suh JD, Turner GA, Wang MB, Taylor-Cousar JL, Saavedra MT, Beswick DM. Patient perspectives on chronic rhinosinusitis in cystic fibrosis: Symptom prioritization in the era of highly effective modulator therapy. Int Forum Allergy Rhinol. 2024 Aug; 14(8):1282-1293.
    View in: PubMed
    Score: 0.006
  64. Ramsey B, Correll CU, DeMaso DR, McKone E, Tullis E, Taylor-Cousar JL, Chu C, Volkova N, Ahluwalia N, Waltz D, Tian S, Mall MA. Elexacaftor/Tezacaftor/Ivacaftor Treatment and Depression-related Events. Am J Respir Crit Care Med. 2024 02 01; 209(3):299-306.
    View in: PubMed
    Score: 0.006
  65. Miller JE, Taylor-Cousar JL, Humphries SM, Khatiwada A, Chen H, Wilson A, Vladar EK, Lynch DA, Li DA, Beswick DM. Chronic rhinosinusitis and olfaction after highly effective modulator therapy: The role of individual sinus inflammation. Int Forum Allergy Rhinol. 2024 May; 14(5):986-989.
    View in: PubMed
    Score: 0.006
  66. Miller JE, Taylor-Cousar JL, Overdevest JB, Khatiwada A, Mace JC, Alt JA, Bodner TE, Chowdhury NI, DiMango EA, Eshaghian PH, Getz AE, Gudis DA, Han EJ, Hwang PH, Keating CL, Khanwalkar A, Kimple AJ, Lee JT, Li D, Markarian K, Norris M, Nayak JV, Owens C, Patel ZM, Poch K, Schlosser RJ, Smith KA, Smith TL, Soler ZM, Suh JD, Tervo JP, Turner GA, Wang MB, Saavedra MT, Beswick DM. Determining the minimal clinically important difference for the questionnaire of olfactory disorders in people with cystic fibrosis and factors associated with improvement after highly effective modulator therapy. Int Forum Allergy Rhinol. 2024 Jun; 14(6):1079-1087.
    View in: PubMed
    Score: 0.006
  67. Daines CL, Tullis E, Costa S, Linnemann RW, Mall MA, McKone EF, Polineni D, Quon BS, Ringshausen FC, Rowe SM, Selvadurai H, Taylor-Cousar JL, Withers NJ, Ahluwalia N, Moskowitz SM, Prieto-Centurion V, Tan YV, Tian S, Weinstock T, Xuan F, Zhang Y, Ramsey B, Griese M. Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one F508del allele: 144-week interim results from a 192-week open-label extension study. Eur Respir J. 2023 12; 62(6).
    View in: PubMed
    Score: 0.006
  68. Miller JE, Liu CM, Zemanick ET, Woods JC, Goss CH, Taylor-Cousar JL, Beswick DM. Olfactory loss in people with cystic fibrosis: Community perceptions and impact. J Cyst Fibros. 2024 Nov; 23(6):1195-1198.
    View in: PubMed
    Score: 0.006
  69. Patil R, Magaret AS, Jain R, Taylor-Cousar J, Hughan KS, Kazmerski TM. Factors associated with pubertal growth outcomes in cystic fibrosis: Early Growth and Puberty in CF. J Cyst Fibros. 2024 May; 23(3):538-544.
    View in: PubMed
    Score: 0.006
  70. Han EJ, Beswick DM, Eshaghian PH, Turner GA, Lee JT, Li DA, Wang MB, Taylor-Cousar JL, Suh JD. Decreases in Rhinology Care Utilization by People with Cystic Fibrosis on Highly Effective Modulator Therapy. Ann Otol Rhinol Laryngol. 2024 Mar; 133(3):340-344.
    View in: PubMed
    Score: 0.006
  71. Kazmerski TM, Stransky OM, Lavage DR, Hughan KS, Jain R, Ladores SL, Stalvey MS, Tangpricha V, Taylor-Cousar JL, West NE, Sawicki GS. Clinician perspectives and practices related to sexual and reproductive care provision for males with cystic fibrosis. J Cyst Fibros. 2024 May; 23(3):417-423.
    View in: PubMed
    Score: 0.006
  72. Beswick DM, Han EJ, Mace JC, Markarian K, Alt JA, Bodner TE, Chowdhury NI, Eshaghian PH, Getz AE, Hwang PH, Khanwalkar A, Kimple AJ, Lee JT, Li DA, Norris M, Nayak JV, Owens C, Patel Z, Poch K, Schlosser RJ, Smith KA, Smith TL, Soler ZM, Suh JD, Turner G, Wang MB, Taylor-Cousar JL, Saavedra M. Factors that predict pursuing sinus surgery in the era of highly effective modulator therapy. Int Forum Allergy Rhinol. 2024 Apr; 14(4):807-818.
    View in: PubMed
    Score: 0.006
  73. Mayer-Hamblett N, Clancy JP, Jain R, Donaldson SH, Fajac I, Goss CH, Polineni D, Ratjen F, Quon BS, Zemanick ET, Bell SC, Davies JC, Jain M, Konstan MW, Kerper NR, LaRosa T, Mall MA, McKone E, Pearson K, Pilewski JM, Quittell L, Rayment JH, Rowe SM, Taylor-Cousar JL, Retsch-Bogart G, Downey DG. Advancing the pipeline of cystic fibrosis clinical trials: a new roadmap with a global trial network perspective. Lancet Respir Med. 2023 10; 11(10):932-944.
    View in: PubMed
    Score: 0.006
  74. Costa E, Girotti S, van den Ham HA, Cipolli M, van der Ent CK, Taylor-Cousar JL, Leufkens HGM. Traits, trends and hits of orphan drug designations in cystic fibrosis. J Cyst Fibros. 2023 09; 22(5):949-957.
    View in: PubMed
    Score: 0.006
  75. Goralski JL, Hoppe JE, Mall MA, McColley SA, McKone E, Ramsey B, Rayment JH, Robinson P, Stehling F, Taylor-Cousar JL, Tullis E, Ahluwalia N, Chin A, Chu C, Lu M, Niu T, Weinstock T, Ratjen F, Rosenfeld M. Phase 3 Open-Label Clinical Trial of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged 2-5 Years with Cystic Fibrosis and at Least One F508del Allele. Am J Respir Crit Care Med. 2023 07 01; 208(1):59-67.
    View in: PubMed
    Score: 0.005
  76. Peng G, Taylor-Cousar JL, Lee M, Keller A, West NE, Kazmerski TM, Goralski JL, Aitken ML, Roe AH, Hadjiliadis D, Uluer A, Flume PA, Mody S, Bray LA, Jain R. Association between unplanned pregnancies and maternal exacerbations in cystic fibrosis. J Cyst Fibros. 2023 09; 22(5):796-803.
    View in: PubMed
    Score: 0.005
  77. Stransky OM, Benipal S, Pam M, Taylor-Cousar JL, Documet P, Kazmerski TM. "Find ways to work parenting into cystic fibrosis": A PhotoVoice exploration of being a parent and having CF. Pediatr Pulmonol. 2023 05; 58(5):1527-1534.
    View in: PubMed
    Score: 0.005
  78. Jordan KD, Zemanick ET, Taylor-Cousar JL, Hoppe JE. Managing cystic fibrosis in children aged 6-11yrs: a critical review of elexacaftor/tezacaftor/ivacaftor combination therapy. Expert Rev Respir Med. 2023 02; 17(2):97-108.
    View in: PubMed
    Score: 0.005
  79. Uluer AZ, MacGregor G, Azevedo P, Indihar V, Keating C, Mall MA, McKone EF, Ramsey BW, Rowe SM, Rubenstein RC, Taylor-Cousar JL, Tullis E, Yonker LM, Chu C, Lam AP, Nair N, Sosnay PR, Tian S, Van Goor F, Viswanathan L, Waltz D, Wang LT, Xi Y, Billings J, Horsley A. Safety and efficacy of vanzacaftor-tezacaftor-deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials. Lancet Respir Med. 2023 06; 11(6):550-562.
    View in: PubMed
    Score: 0.005
  80. Prochownik K, Jain R, Taylor-Cousar JL, Lavage DR, Stransky OM, Thomas HN, Kazmerski TM. Menopause in people with cystic fibrosis. Menopause. 2023 04 01; 30(4):401-405.
    View in: PubMed
    Score: 0.005
  81. Gill AS, Alt JA, Detwiller KY, Rowan NR, Gray ST, Hellings PW, Joshi SR, Lee JT, Soler ZM, Tan BK, Taylor-Cousar JL, Wise SK, Wu TJ, Beswick DM. Management paradigms for chronic rhinosinusitis in individuals with asthma: An evidence-based review with recommendations. Int Forum Allergy Rhinol. 2023 09; 13(9):1758-1782.
    View in: PubMed
    Score: 0.005
  82. Gifford AH, Taylor-Cousar JL, Davies JC, McNally P. Update on Clinical Outcomes of Highly Effective Modulator Therapy. Clin Chest Med. 2022 12; 43(4):677-695.
    View in: PubMed
    Score: 0.005
  83. Mayer-Hamblett N, Ratjen F, Russell R, Donaldson SH, Riekert KA, Sawicki GS, Odem-Davis K, Young JK, Rosenbluth D, Taylor-Cousar JL, Goss CH, Retsch-Bogart G, Clancy JP, Genatossio A, O'Sullivan BP, Berlinski A, Millard SL, Omlor G, Wyatt CA, Moffett K, Nichols DP, Gifford AH. Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials. Lancet Respir Med. 2023 04; 11(4):329-340.
    View in: PubMed
    Score: 0.005
  84. Jain R, Wolf A, Molad M, Taylor-Cousar J, Esther CR, Shteinberg M. Congenital bilateral cataracts in newborns exposed to elexacaftor-tezacaftor-ivacaftor in utero and while breast feeding. J Cyst Fibros. 2022 11; 21(6):1074-1076.
    View in: PubMed
    Score: 0.005
  85. Kazmerski TM, Stransky OM, Lavage DR, Taylor-Cousar JL, Sawicki GS, Ladores SL, Godfrey EM, Aitken ML, Fields A, Sufian S, Jain M, Barto TL, Billings J, Hadjiliadis D, Jain R. Sexual and reproductive health experiences and care of adult women with cystic fibrosis. J Cyst Fibros. 2023 03; 22(2):223-233.
    View in: PubMed
    Score: 0.005
  86. Montemayor K, Kazmerski TM, Riekert KA, Psoter KJ, Jain R, Taylor-Cousar JL, Aitken ML, Boyle RL, Patel S, West NE. Clinician attitudes and practices on pregnancy planning and care in cystic fibrosis. J Cyst Fibros. 2023 03; 22(2):201-206.
    View in: PubMed
    Score: 0.005
  87. Izquierdo ME, Marion CR, Moore WC, Raraigh KS, Taylor-Cousar JL, Cutting GR, Ampleford E, Hawkins GA, Zein J, Castro M, Denlinger LC, Erzurum SC, Fahy JV, Israel E, Jarjour NN, Mauger D, Levy BD, Wenzel SE, Woodruff P, Bleecker ER, Meyers DA, Ortega VE. DNA sequencing analysis of cystic fibrosis transmembrane conductance regulator gene identifies cystic fibrosis-associated variants in the Severe Asthma Research Program. Pediatr Pulmonol. 2022 07; 57(7):1782-1788.
    View in: PubMed
    Score: 0.005
  88. Caceres SM, Sanders LA, Rysavy NM, Poch KR, Jones CR, Pickard K, Fingerlin TE, Marcus RA, Malcolm KC, Taylor-Cousar JL, Nichols DP, Nick JA, Strand M, Saavedra MT. Blood mRNA biomarkers distinguish variable systemic and sputum inflammation at treatment initiation of inhaled antibiotics in cystic fibrosis: A prospective non-randomized trial. PLoS One. 2022; 17(5):e0267592.
    View in: PubMed
    Score: 0.005
  89. West NE, Kazmerski TM, Taylor-Cousar JL, Tangpricha V, Pearson K, Aitken ML, Jain R. Optimizing sexual and reproductive health across the lifespan in people with cystic fibrosis. Pediatr Pulmonol. 2022 02; 57 Suppl 1:S89-S100.
    View in: PubMed
    Score: 0.005
  90. Elborn JS, Konstan MW, Taylor-Cousar JL, Fajac I, Horsley A, Sutharsan S, Aaron SD, Daines CL, Uluer A, Downey DG, Lucidi VV, Ahuja S, Springman E, Mershon J, Grosswald R, Rowe SM. Empire-CF study: A phase 2 clinical trial of leukotriene A4 hydrolase inhibitor acebilustat in adult subjects with cystic fibrosis. J Cyst Fibros. 2021 11; 20(6):1026-1034.
    View in: PubMed
    Score: 0.005
  91. Barry PJ, Mall MA, ?lvarez A, Colombo C, de Winter-de Groot KM, Fajac I, McBennett KA, McKone EF, Ramsey BW, Sutharsan S, Taylor-Cousar JL, Tullis E, Ahluwalia N, Jun LS, Moskowitz SM, Prieto-Centurion V, Tian S, Waltz D, Xuan F, Zhang Y, Rowe SM, Polineni D. Triple Therapy for Cystic Fibrosis Phe508del-Gating and -Residual Function Genotypes. N Engl J Med. 2021 08 26; 385(9):815-825.
    View in: PubMed
    Score: 0.005
  92. Derichs N, Taylor-Cousar JL, Davies JC, Fajac I, Tullis E, Nazareth D, Downey DG, Rosenbluth D, Malfroot A, Saunders C, Jensen R, Solomon GM, Vermeulen F, Kaiser A, Willmann S, Saleh S, Droebner K, Sandner P, Bear CE, Hoffmann A, Ratjen F, Rowe SM. Riociguat for the treatment of Phe508del homozygous adults with cystic fibrosis. J Cyst Fibros. 2021 11; 20(6):1018-1025.
    View in: PubMed
    Score: 0.005
  93. Shteinberg M, Taylor-Cousar JL, Durieu I, Cohen-Cymberknoh M. Fertility and Pregnancy in Cystic Fibrosis. Chest. 2021 12; 160(6):2051-2060.
    View in: PubMed
    Score: 0.005
  94. Zemanick ET, Taylor-Cousar JL, Davies J, Gibson RL, Mall MA, McKone EF, McNally P, Ramsey BW, Rayment JH, Rowe SM, Tullis E, Ahluwalia N, Chu C, Ho T, Moskowitz SM, Noel S, Tian S, Waltz D, Weinstock TG, Xuan F, Wainwright CE, McColley SA. A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele. Am J Respir Crit Care Med. 2021 06 15; 203(12):1522-1532.
    View in: PubMed
    Score: 0.005
  95. Poore TS, Taylor-Cousar JL, Zemanick ET. Cardiovascular complications in cystic fibrosis: A review of the literature. J Cyst Fibros. 2022 01; 21(1):18-25.
    View in: PubMed
    Score: 0.005
  96. Griese M, Costa S, Linnemann RW, Mall MA, McKone EF, Polineni D, Quon BS, Ringshausen FC, Taylor-Cousar JL, Withers NJ, Moskowitz SM, Daines CL. Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More F508del Alleles: Interim Results of an Open-Label Phase 3 Clinical Trial. Am J Respir Crit Care Med. 2021 02 01; 203(3):381-385.
    View in: PubMed
    Score: 0.005
  97. Khan FN, Tangpricha V, Hughan KS, Jain R, Ladores SL, Taylor-Cousar JL, West NE, Montemayor K, Sawicki GS, Uluer A, Aitken ML, Shnorhavorian M, Bray LA, Kvam C, Stalvey M, Kazmerski TM. Men's health in the modern era of cystic fibrosis. J Cyst Fibros. 2021 11; 20(6):e121-e123.
    View in: PubMed
    Score: 0.005
  98. McCoy KS, Heijerman H, Taylor-Cousar JL, Waltz D, Sosnay PR, Ramsey BW, Rowe S, Welter J. Transparency and diversity in cystic fibrosis research - Authors' reply. Lancet. 2020 08 29; 396(10251):602.
    View in: PubMed
    Score: 0.005
  99. Mayer-Hamblett N, van Koningsbruggen-Rietschel S, Nichols DP, VanDevanter DR, Davies JC, Lee T, Durmowicz AG, Ratjen F, Konstan MW, Pearson K, Bell SC, Clancy JP, Taylor-Cousar JL, De Boeck K, Donaldson SH, Downey DG, Flume PA, Drevinek P, Goss CH, Fajac I, Magaret AS, Quon BS, Singleton SM, VanDalfsen JM, Retsch-Bogart GZ. Building global development strategies for cf therapeutics during a transitional cftr modulator era. J Cyst Fibros. 2020 09; 19(5):677-687.
    View in: PubMed
    Score: 0.004
  100. Langawi MA, Byrnes C, Davies JC, Hamouda S, Kabra M, Rached SZ, Sands D, Shteinberg M, Taylor-Cousar J, Tullis E, Wainwright C. 'Go for it, dream big, work hard and persist': A message to the next generation of CF leaders in recognition of International Women's Day 2020. J Cyst Fibros. 2020 03; 19(2):184-193.
    View in: PubMed
    Score: 0.004
  101. Godfrey EM, Mody S, Schwartz MR, Heltshe SL, Taylor-Cousar JL, Jain R, Sufian S, Josephy T, Aitken ML. Contraceptive use among women with cystic fibrosis: A pilot study linking reproductive health questions to the Cystic Fibrosis Foundation National Patient Registry. Contraception. 2020 06; 101(6):420-426.
    View in: PubMed
    Score: 0.004
  102. Heijerman HGM, McKone EF, Downey DG, Van Braeckel E, Rowe SM, Tullis E, Mall MA, Welter JJ, Ramsey BW, McKee CM, Marigowda G, Moskowitz SM, Waltz D, Sosnay PR, Simard C, Ahluwalia N, Xuan F, Zhang Y, Taylor-Cousar JL, McCoy KS. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet. 2019 11 23; 394(10212):1940-1948.
    View in: PubMed
    Score: 0.004
  103. Middleton PG, Mall MA, Drev?nek P, Lands LC, McKone EF, Polineni D, Ramsey BW, Taylor-Cousar JL, Tullis E, Vermeulen F, Marigowda G, McKee CM, Moskowitz SM, Nair N, Savage J, Simard C, Tian S, Waltz D, Xuan F, Rowe SM, Jain R. Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. N Engl J Med. 2019 11 07; 381(19):1809-1819.
    View in: PubMed
    Score: 0.004
  104. Somayaji R, Russell R, Cogen JD, Goss CH, Nick SE, Saavedra MT, Taylor-Cousar JL, Nick JA, Nichols DP. Oral Azithromycin Use and the Recovery of Lung Function from Pulmonary Exacerbations Treated with Intravenous Tobramycin or Colistimethate in Adults with Cystic Fibrosis. Ann Am Thorac Soc. 2019 07; 16(7):853-860.
    View in: PubMed
    Score: 0.004
  105. Liou TG, Adler FR, Argel N, Asfour F, Brown PS, Chatfield BA, Daines CL, Durham D, Francis JA, Glover B, Heynekamp T, Hoidal JR, Jensen JL, Keogh R, Kopecky CM, Lechtzin N, Li Y, Lysinger J, Molina O, Nakamura C, Packer KA, Poch KR, Quittner AL, Radford P, Redway AJ, Sagel SD, Sprandel S, Taylor-Cousar JL, Vroom JB, Yoshikawa R, Clancy JP, Elborn JS, Olivier KN, Cox DR. Prospective multicenter randomized patient recruitment and sample collection to enable future measurements of sputum biomarkers of inflammation in an observational study of cystic fibrosis. BMC Med Res Methodol. 2019 04 26; 19(1):88.
    View in: PubMed
    Score: 0.004
  106. Pohl K, Nichols DP, Taylor-Cousar JL, Saavedra MT, Strand MJ, Nick JA, Bratcher PE. Corticosteroid use and increased CXCR2 levels on leukocytes are associated with lumacaftor/ivacaftor discontinuation in cystic fibrosis patients homozygous for the F508del CFTR mutation. PLoS One. 2018; 13(12):e0209026.
    View in: PubMed
    Score: 0.004
  107. Keating D, Marigowda G, Burr L, Daines C, Mall MA, McKone EF, Ramsey BW, Rowe SM, Sass LA, Tullis E, McKee CM, Moskowitz SM, Robertson S, Savage J, Simard C, Van Goor F, Waltz D, Xuan F, Young T, Taylor-Cousar JL. VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles. N Engl J Med. 2018 10 25; 379(17):1612-1620.
    View in: PubMed
    Score: 0.004
  108. Davies JC, Moskowitz SM, Brown C, Horsley A, Mall MA, McKone EF, Plant BJ, Prais D, Ramsey BW, Taylor-Cousar JL, Tullis E, Uluer A, McKee CM, Robertson S, Shilling RA, Simard C, Van Goor F, Waltz D, Xuan F, Young T, Rowe SM. VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles. N Engl J Med. 2018 10 25; 379(17):1599-1611.
    View in: PubMed
    Score: 0.004
  109. Saavedra MT, Quon BS, Faino A, Caceres SM, Poch KR, Sanders LA, Malcolm KC, Nichols DP, Sagel SD, Taylor-Cousar JL, Leach SM, Strand M, Nick JA. Whole Blood Gene Expression Profiling Predicts Severe Morbidity and Mortality in Cystic Fibrosis: A 5-Year Follow-Up Study. Ann Am Thorac Soc. 2018 05; 15(5):589-598.
    View in: PubMed
    Score: 0.004
  110. Nichols DP, Happoldt CL, Bratcher PE, Caceres SM, Chmiel JF, Malcolm KC, Saavedra MT, Saiman L, Taylor-Cousar JL, Nick JA. Impact of azithromycin on the clinical and antimicrobial effectiveness of tobramycin in the treatment of cystic fibrosis. J Cyst Fibros. 2017 May; 16(3):358-366.
    View in: PubMed
    Score: 0.003
  111. Nick JA, Caceres SM, Kret JE, Poch KR, Strand M, Faino AV, Nichols DP, Saavedra MT, Taylor-Cousar JL, Geraci MW, Burnham EL, Fessler MB, Suratt BT, Abraham E, Moss M, Malcolm KC. Extremes of Interferon-Stimulated Gene Expression Associate with Worse Outcomes in the Acute Respiratory Distress Syndrome. PLoS One. 2016; 11(9):e0162490.
    View in: PubMed
    Score: 0.003
  112. Ferril GR, Nick JA, Getz AE, Barham HP, Saavedra MT, Taylor-Cousar JL, Nichols DP, Curran-Everett D, Kingdom TT, Ramakrishnan VR. Comparison of radiographic and clinical characteristics of low-risk and high-risk cystic fibrosis genotypes. Int Forum Allergy Rhinol. 2014 Nov; 4(11):915-20.
    View in: PubMed
    Score: 0.003
  113. Caceres SM, Malcolm KC, Taylor-Cousar JL, Nichols DP, Saavedra MT, Bratton DL, Moskowitz SM, Burns JL, Nick JA. Enhanced in vitro formation and antibiotic resistance of nonattached Pseudomonas aeruginosa aggregates through incorporation of neutrophil products. Antimicrob Agents Chemother. 2014 Nov; 58(11):6851-60.
    View in: PubMed
    Score: 0.003
  114. Nick JA, Moskowitz SM, Chmiel JF, Forss?n AV, Kim SH, Saavedra MT, Saiman L, Taylor-Cousar JL, Nichols DP. Azithromycin may antagonize inhaled tobramycin when targeting Pseudomonas aeruginosa in cystic fibrosis. Ann Am Thorac Soc. 2014 Mar; 11(3):342-50.
    View in: PubMed
    Score: 0.003
  115. Nick JA, Sanders LA, Ickes B, Briones NJ, Caceres SM, Malcolm KC, Brayshaw SJ, Chacon CS, Barboa CM, Jones MC, St Clair C, Taylor-Cousar JL, Nichols DP, Sagel SD, Strand M, Saavedra MT. Blood mRNA biomarkers for detection of treatment response in acute pulmonary exacerbations of cystic fibrosis. Thorax. 2013 Oct; 68(10):929-37.
    View in: PubMed
    Score: 0.003
  116. Malcolm KC, Nichols EM, Caceres SM, Kret JE, Martiniano SL, Sagel SD, Chan ED, Caverly L, Solomon GM, Reynolds P, Bratton DL, Taylor-Cousar JL, Nichols DP, Saavedra MT, Nick JA. Mycobacterium abscessus induces a limited pattern of neutrophil activation that promotes pathogen survival. PLoS One. 2013; 8(2):e57402.
    View in: PubMed
    Score: 0.003
  117. Rasouli N, Seggelke S, Gibbs J, Hawkins RM, Casciano ML, Cohlmia E, Taylor-Cousar J, Wang C, Pereira R, Hsia E, Draznin B. Cystic fibrosis-related diabetes in adults: inpatient management of 121 patients during 410 admissions. J Diabetes Sci Technol. 2012 Sep 01; 6(5):1038-44.
    View in: PubMed
    Score: 0.003
  118. Young RL, Malcolm KC, Kret JE, Caceres SM, Poch KR, Nichols DP, Taylor-Cousar JL, Saavedra MT, Randell SH, Vasil ML, Burns JL, Moskowitz SM, Nick JA. Neutrophil extracellular trap (NET)-mediated killing of Pseudomonas aeruginosa: evidence of acquired resistance within the CF airway, independent of CFTR. PLoS One. 2011; 6(9):e23637.
    View in: PubMed
    Score: 0.002
  119. Nick JA, Chacon CS, Brayshaw SJ, Jones MC, Barboa CM, St Clair CG, Young RL, Nichols DP, Janssen JS, Huitt GA, Iseman MD, Daley CL, Taylor-Cousar JL, Accurso FJ, Saavedra MT, Sontag MK. Effects of gender and age at diagnosis on disease progression in long-term survivors of cystic fibrosis. Am J Respir Crit Care Med. 2010 Sep 01; 182(5):614-26.
    View in: PubMed
    Score: 0.002
  120. Ornatowski W, Poschet JF, Perkett E, Taylor-Cousar JL, Deretic V. Elevated furin levels in human cystic fibrosis cells result in hypersusceptibility to exotoxin A-induced cytotoxicity. J Clin Invest. 2007 Nov; 117(11):3489-97.
    View in: PubMed
    Score: 0.002
  121. Poschet JF, Timmins GS, Taylor-Cousar JL, Ornatowski W, Fazio J, Perkett E, Wilson KR, Yu HD, de Jonge HR, Deretic V. Pharmacological modulation of cGMP levels by phosphodiesterase 5 inhibitors as a therapeutic strategy for treatment of respiratory pathology in cystic fibrosis. Am J Physiol Lung Cell Mol Physiol. 2007 Sep; 293(3):L712-9.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)